| Date | Title | Description |
| 19.09.2024 | Telix and Cardinal Health: A New Era in Kidney Cancer Diagnostics | In the ever-evolving landscape of cancer diagnostics, Telix Pharmaceuticals Limited has made a significant move. The Australian biopharmaceutical company has chosen Cardinal Health, Inc. as its U.S. commercial distributor for Zircaix® (TLX2... |
| 19.09.2024 | Promising Advances in Cancer and Heart Failure Treatments: A Look at Harbour BioMed and AnaCardio | In the world of biopharmaceuticals, innovation is the lifeblood. Two companies, Harbour BioMed and AnaCardio, are making waves with their latest clinical trials. Both are pushing the boundaries of treatment for serious health conditions: ad... |
| 18.09.2024 | FASENRA EGPA US FDA APPROVAL | FASENRA EGPA US FDA APPROVAL
Wed, Sep 18, 2024 08:45 CET Report this content
18 September 2024
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60... |
| 18.09.2024 | Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix® | MELBOURNE, Australia, Sept. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical di... |
| 17.09.2024 | DBP International AB: transition of the SI053 clinical trials protocol to a new Clinical Trial Information System has been completed | DBP International AB: transition of the SI053 clinical trials protocol to a new Clinical Trial Information System has been completed
Tue, Sep 17, 2024 07:00 CET Report this content
Double Bond Pharmaceutical International AB (publ) ("D... |
| 17.09.2024 | AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update | AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update
Tue, Sep 17, 2024 08:30 CET Report this content
PRESS RELEASE
Stockholm, Sweden, September 17, 2024
AnaCardio, a Swedish clinical-stage biopharma... |
| 17.09.2024 | FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer | Ad hoc announcement pursuant to Art. 53 LR
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2
Kisqali® (ribo... |
| 16.09.2024 | Pioneering New Frontiers in ALS and Cancer Treatment: The Role of QRL-101 and mIDH1 Inhibitors | In the realm of medical science, innovation is the lifeblood that fuels progress. Two recent developments stand out: QurAlis Corporation's QRL-101 for ALS and Vazyme's contributions to mIDH1 cancer treatment. Both represent significant stri... |
| 16.09.2024 | Positive clinical progress in the biotech scene |
With the dosing of its first patient for lead candidate CDR404, CDR-Life has made significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibo... |
| 14.09.2024 | Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializat... |
| 14.09.2024 | Новый анализ крови может выявить риск сердечно-сосудистых заболеваний за несколько лет до симптомов | Новое исследование показывает, что анализ крови на содержание определенных жиров и маркеров воспаления позволяет предвидеть сердечно-сосудистые заболевания (ССЗ) у женщин за несколько лет до появления симптомов, что является значительным ша... |
| 13.09.2024 | New Frontiers in Cancer Imaging and Treatment: A Look at SECuRE and ZIRCON Trials | In the ever-evolving landscape of cancer treatment, two recent trials have emerged as beacons of hope. The SECuRE trial and the ZIRCON trial are paving the way for innovative therapies and diagnostic tools that could redefine patient care. ... |
| 12.09.2024 | Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares | Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares
Paris (France) et Houston (Texas), le 12 septembre 2024. Dans le cadre d... |
| 12.09.2024 | Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative treatments for people... |
| 12.09.2024 | SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort | Highlights
Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67Cu-SAR-bisPSMA at the highest dose of 12GBq.
The Safety Review Committee (SRC) assessed early data from the first 3 participants in cohort 4 who received 2 ... |
| 11.09.2024 | Building Bridges in Cancer Care: The Push for Diversity and Inclusion | In the heart of Washington, D.C., a significant conversation unfolded at the National Comprehensive Cancer Network (NCCN) Policy Summit. The focus? Diversity, equity, and inclusion (DEI) in oncology. This summit was not just another meeting... |
| 11.09.2024 | 'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology | MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting ... |
| 11.09.2024 | TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease | The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5
TREMFYA® is now... |
| 10.09.2024 | QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS | QRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients
Completed Phase 1 single-ascending dose (SAD) clinical trial of QRL-101 enrolled 88 participants; no report... |
| 10.09.2024 | Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) | Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management
SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- J... |
| 10.09.2024 | Molecular Profiling May Improve Meningioma Decisionmaking | Investigators have demonstrated how molecular profiling tumors can be used to help predict treatment response and survival in patients with meningiomas, the most common type of primary brain tumor, according to a recent study published in N... |
| 07.09.2024 | CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab | Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunit... |
| 06.09.2024 | Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium | New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression
Arimoclomol ... |
| 05.09.2024 | Promising Advances in Cancer Treatment: A Look at TiNivo-2 and TLX101 | In the ever-evolving landscape of cancer treatment, two recent studies stand out like beacons of hope. The TiNivo-2 trial by AVEO Oncology and the IPAX-1 study by Telix Pharmaceuticals both unveil new possibilities for patients battling agg... |
| 05.09.2024 | BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 | MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESM... |
| 05.09.2024 | BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio | MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom 13. bis 17. September 2024 in Barcelona,... |
| 04.09.2024 | IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances | MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety an... |
| 03.09.2024 | IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances | MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safe... |
| 03.09.2024 | AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024 | BOSTON, Sept. 3, 2024 /PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the ... |
| 02.09.2024 | Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis | Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
In the HERCULES study, tolebrutinib met the primary end... |
| 02.09.2024 | Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis | Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
In the HERCULES study, tolebrutinib met the primary end... |
| 02.09.2024 | CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des p... | Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes présentant une sclérose en plaqu... |
| 28.08.2024 | Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent | MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) fo... |
| 14.08.2024 | Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep | Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep
Wed, Aug 14, 2024 08:30 CET Report this content
• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoi... |
| 14.08.2024 | Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update | - First patient treated in May for liver metastases from colorectal cancer -
- Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers, with an overall response rate of almo... |
| 12.08.2024 | Linshom Medical Completes Clinical Study Enrollment at The Ohio State University Wexner Medical Center | BALTIMORE, MARYLAND, US, August 12, 2024 /EINPresswire.com/ -- The study, “Advanced Prediction of Respiratory Depression Episodes with the Linshom Continuous Predictive Respiratory Sensor”, completed enrollment of 508 patients well ahead of... |
| 12.08.2024 | Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose
$28.7 million in cash and cash equivalents as of June 30, 2024 with cash ... |
| 08.08.2024 | Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy
Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic ... |
| 08.08.2024 | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results | Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25
IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H’26
Phas... |
| 08.08.2024 | Vincerx Pharma Reports Second Quarter 2024 Financial Results | Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024
Expected cash runwa... |
| 08.08.2024 | Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant | Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combination with standard-of-care lenalidomide, bo... |
| 08.08.2024 | SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we expect to receive in Q3 20... |
| 07.08.2024 | Healionics announces 12-month clinical results for STARgraft | STARgraft vascular graft
SEATTLE, WA, USA, August 7, 2024 /EINPresswire.com/ -- Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced 12-month clinical results in the ongoing human trial of its ... |
| 07.08.2024 | Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) | Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p |
| 07.08.2024 | Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results | Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast
Positive long-term data from INTEGRIS-PSC 320 mg dose group d... |
| 07.08.2024 | Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) | Ad hoc announcement pursuant to Art. 53 LR
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. ... |
| 06.08.2024 | Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update | -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 --
-- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 ... |
| 05.08.2024 | Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update | Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024
New SPR720 in-vitro resistance data to be presented at I... |
| 30.07.2024 | Drug Application and Approval Process - "Questions and Answers" | How do I report adverse events associated with the use of a drug?
FDA’s MedWatch Web site provides various means for voluntary reporting of serious postmarketing adverse events, product quality problems, product use error, or therapeutic in... |
| 30.07.2024 | Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis | SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollmen... |
| 28.07.2024 | New Frontiers in Cancer Treatment: Breakthroughs from Harbour BioMed and Astellas Pharma | In the relentless battle against cancer, innovation is the sword that cuts through despair. Two recent announcements from Harbour BioMed and Astellas Pharma illuminate the path forward, showcasing novel therapies that could reshape treatmen... |
| 26.07.2024 | Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer | - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union
- A decision on the EU marketing authorization is expected by October 2024
TOKYO, July 26, 2024 ... |
| 26.07.2024 | Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializat... |
| 26.07.2024 | GO2 for Lung Cancer Honors Dr. Pasi A. Jӓnne with 2024 Bonnie J. Addario Lectureship Award | Pasi A. Jӓnne, M.D, Ph.D., recipient of the 2024 Bonnie J. Addario Lectureship Award
Dr. Jӓnne has had a remarkable impact on identifying risks for lung cancer through his groundbreaking research.”
— Bonnie J. Addario, co-founder and board ... |
| 25.07.2024 | Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializat... |
| 25.07.2024 | Idorsia announces financial results for the first half 2024 | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – July 25, 2024
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024.
Business highlights
Viatris collaboration: Global research and devel... |
| 19.07.2024 | Knockout of CD5 on CAR T Cells Boosts Anti-Tumor Efficacy | PHILADELPHIA – The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, ... |
| 16.07.2024 | CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab | Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion Growth Opportunitie... |
| 08.07.2024 | Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics | HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmac... |
| 08.07.2024 | PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors | PMC-309 receives safety approval for first dose cohort (0.2mg/kg), and second dose cohort (0.5mg/kg) is currently underway in Australia.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stag... |
| 01.07.2024 | Lynparza & Imfinzi positive CHMP in endometrial | Lynparza & Imfinzi positive CHMP in endometrial
Mon, Jul 01, 2024 08:00 CET Report this content
1 July 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advance... |
| 28.06.2024 | Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients | HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceu... |
| 26.06.2024 | GenieUs Genomics, Duke and Temple Universities - Tackle ALS Heterogeneity with Genomic Profiling in New Clinical Trial | Deep Sequencing from PacBio used by GenieUs Genomics, Duke University and Temple University for a Precision Health Approach in ALS Clinical Trial
SYDNEY, NSW, AUSTRALIA, June 26, 2024 /EINPresswire.com/ -- GenieUs Genomics (GenieUs), in col... |
| 25.06.2024 | Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024 | SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 25.06.2024 | Breakthrough T1D-Funded Research Featured at American Diabetes Association 84th Scientific Sessions | NEW YORK, June 25, 2024 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the America... |
| 24.06.2024 | iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson's Disease | WUHAN, China, June 24, 2024 /PRNewswire/ -- On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's Disease. This ma... |
| 24.06.2024 | Woman at Pittsburgh hospital becomes first to receive vaccine for early-stage breast cancer | North Hills woman becomes first to receive vaccine for early-stage breast cancer
North Hills woman becomes first to receive vaccine for early-stage breast cancer 01:58
PITTSBURGH (KDKA) — A woman from the North Hills became the first to rec... |
| 19.06.2024 | Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing’s disease trial | Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing’s disease trial
Wed, Jun 19, 2024 08:30 CET Report this content
Lundbeck is exploring a new area in neurohormonal dysfunctions by initiating a phase II trial using Lu AG... |
| 17.06.2024 | Imfinzi approved in the US for endometrial cancer | Imfinzi approved in the US for endometrial cancer
Mon, Jun 17, 2024 08:00 CET Report this content
17 June 2024
Imfinzi plus chemotherapy approved in the US for
mismatch repair deficient advanced or recurrent endometrial cancer
Approval base... |
| 17.06.2024 | FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis-a Chronic Rare Disease in Nephrology | -- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients CLEVELAND, OHIO, UNITED STATES, June 17, 2024 /EINPresswire.com/ -- NovelMed proudly announces ... |
| 12.06.2024 | Kardium nets $104M for its spherical pulsed field ablation catheter | Shortly after announcing positive clinical trial data from its pulsed field ablation treatment for irregular heart rhythms, Kardium has more good news to share: the company has secured $104 million in new funding.
The proceeds will finance ... |
| 11.06.2024 | Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 | --Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41
--Significant and clinically meaningful re... |
| 05.06.2024 | Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress | Highlights from the Data Presentation
Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of VRON-0200
VRON-0200 was wel... |
| 04.06.2024 | DBP International AB and Vivo Biopharma LLC: Revised Asset Purchase and Collaboration Agreements | DBP International AB and Vivo Biopharma LLC: Revised Asset Purchase and Collaboration Agreements
Tue, Jun 04, 2024 06:30 CET Report this content
Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), tod... |
| 04.06.2024 | Elemind’s neurotech headband puts you to sleep when you want | GamesBeat is excited to partner with Lil Snack to have customized games just for our audience! We know as gamers ourselves, this is an exciting way to engage through play with the GamesBeat content you have already come to love. Start playi... |
| 03.06.2024 | Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 | ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, le... |
| 03.06.2024 | Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging | MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food a... |
| 03.06.2024 | Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […] | ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une t... |
| 03.06.2024 | Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 01.06.2024 | ASCO: New ‘Armored’ CAR produces significant responses | The “armored” huCART19-IL18 is an anti-CD19 CAR that was further modified to secrete the pro-inflammatory cytokine, interleukin 18 (IL 18).
CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including no... |
| 31.05.2024 | SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis | ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of AKANTIOR® (po... |
| 31.05.2024 | Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer | TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.
Reported median radiographic progression-free survival (rP... |
| 29.05.2024 | Клетка XVIII. Прионы | Для разговора о прионах, необходимо осознавать многие моменты и положения связанные с ними в окружающей нас действительности. В рамках ограниченного объема статьи мы не сможем с одинаковым уровнем подробности изложить все полезные сведения ... |
| 28.05.2024 | First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data: NASDAQ: NRXP | $NRXP on the NASDAQ
$NRXP Pipeline
$NRXP Founder, Director and CSO
$NRXP Research Report
NASDAQ: $NRXP Hope Science Life
Breakthrough Antidepressant by NRx Pharmaceuticals Proven to Lower Suicide Risk in Bipolar Patients: NRx Pharmaceutical... |
| 28.05.2024 | Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD | KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental p... |
| 27.05.2024 | Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma | Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first an... |
| 27.05.2024 | Dato-DXd improved OS in nonsquamous lung cancer | Dato-DXd improved OS in nonsquamous lung cancer
Mon, May 27, 2024 08:00 CET Report this content
This announcement contains inside information
27 May 2024
Datopotamab deruxtecan showed clinically meaningful overall survival
improvement vs. c... |
| 27.05.2024 | Regenefro Co., Ltd. Regenefro begins recruiting subjects for the second stage of the early phase II clinical trial of its ADPKD treatment drug | - |
| 27.05.2024 | Regenefro Co., Ltd. Regenefro begins recruiting subjects for the second stage of the early phase II clinical trial of its ADPKD treatment drug | Regenefro Co., Ltd.
Regenefro begins recruiting subjects for the second stage of early phase 2 clinical trial of ADPKD treatment drug
……
Regenephro Co., Ltd. (https://www.regenephro.co.jp/) will begin recruiting subjects from April for the ... |
| 27.05.2024 | Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation... | La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation L’examen prioritaire accordé par la FDA est motivé par les résulta... |
| 25.05.2024 | Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio | In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 week... |
| 24.05.2024 | Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting | The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
Updated results from the ELECTRA study, evaluating elacestrant in combination with ab... |
| 24.05.2024 | Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor | SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 tri... |
| 24.05.2024 | Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting | The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
Updated results from the ELECTRA study, evaluating elacestrant in combination with ab... |
| 24.05.2024 | Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor | SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 tri... |
| 23.05.2024 | Further CYP-001 GvHD Clinical Data Published in Nature Medicine | Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%
MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a cl... |
| 23.05.2024 | Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly | Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
Thu, May 23, 2024 11:30 CET Report this content
Lund, Sweden — 23 May 2024 — Camurus (NASDAQ STO: CAMX) today announced that the... |
| 22.05.2024 | Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human Clinical Trials | FREDERICK, Md., May 22, 2024 /PRNewswire/ -- Theradaptive, Inc., a regenerative medicine company developing targeted therapeutics, announced today it has been awarded funding from the Maryland Stem Cell Research Fund (MSCRF) to support huma... |
| 21.05.2024 | Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer | CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.
Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently... |
